Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541167/
Alexey Boyko, Academic Editor Metabolomics-based technologies map in vivo biochemical changes that may be used as early indicators of pathological abnormalities prior to the development of clinical symptoms in neurological...
In this review, we offer evidence in support of metabolites that are described as potential biomarkers in the literature of MS biofluids upstream regulators, and show novel, still unexplored metabolic pathways, whose investigation may open novel avenues of research.
Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34720605/
1 Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA. 2 Autoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, USA. 3 Graduate Program...
Conclusions: These differences may facilitate personalized precision medicine and aid in the discovery of new therapeutic targets for disease progression through the improvement of patient stratification.
Conclusions: Performance in information processing speed might help to identify patients at risk for physical impairment. Therefore, neuropsychological assessment should be integrated in clinical standard care to support disease management in pwMS.
Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression - Cellular and Molecular Neurobiology
Source : https://link.springer.com/article/10.1007/s10571-021-01158-4
The issue of treating Multiple Sclerosis (MS) begins with disease-modifying treatments (DMTs) which may cause lymphopenia, dyspnea, and many other adverse effects. Consequently, further identification and evaluation of alternative treatments...